Physician profile
Robert Goodman
NPI 1760434013
$5,389.80
in general payments reported to CMS, 2019-2025
34 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $631 · 2021: $920 · 2022: $594 · 2023: $960 · 2024: $689 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.52 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $660.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $636.67 | 2020-2025 | |
| Novo Nordisk INC | $538.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $446.59 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $318.28 | 2019-2023 | Verquvo, Belsomra |
| Dexcom, INC. | $294.74 | 2021-2023 | Dexcom G7 Gss (161) |
| Pfizer INC. | $270.75 | 2019-2025 | |
| Amarin Pharma, INC. | $223.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.69 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $184.10 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.45 | 2021-2024 | |
| Boston Scientific Corporation | $160.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $116.89 | 2023-2024 | Rexulti, Jynarque |
| Ironwood Pharmaceuticals, INC | $113.01 | 2021-2024 | Linzess |
| Exact Sciences Corporation | $103.15 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $100.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $93.22 | 2019-2020 | |
| Vifor Pharma, INC. | $92.73 | 2019-2024 | Veltassa |
| Amgen INC. | $79.86 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $74.76 | 2019-2022 | |
| Insightec,INC | $70.62 | 2023-2024 | Exablate |
| Mallinckrodt Hospital Products INC. | $69.17 | 2021-2022 | |
| Horizon Therapeutics Plc | $50.49 | 2022 | |
| Medtronic USA, INC. | $40.60 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $36.63 | 2023 | Kristalose |
| Allergan, INC. | $36.30 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.11 | 2020-2023 | Vpriv |
| Shire North American Group INC | $30.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.44 | 2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $24.58 | 2023 | |
| Eisai INC. | $19.62 | 2021 | |
| Biotronik Nro, INC. | $19.60 | 2025 | Prospera |
| Nestle Healthcare Nutrition INC. | $16.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.